April 25, 2013

Zr-89 Trastuzumab PET monitors radioimmunotherapy for gastric cancer

 April 24th, Kathy Fay Mahdoubi reported in Health Imaging, “For patients testing positive for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer undergoing treatment with the tyrosine kinase inhibitor afatinib, therapy monitoring using PET and the radiopharmaceutical Zr-89 Trastuzumab can effectively assess tumor activity and improve staging of disease, according to research published online April 11 in The Journal of Nuclear Medicine.”